Rheumatologist Financial Planning: Infusion Center Ownership, PSLF, and Retirement Stacking

Rheumatology occupies an unusual position in physician finance: it is a lower-paid specialty by traditional compensation metrics, yet it contains one of the most structurally significant income opportunities in office-based medicine — in-office biologic infusion. A rheumatologist who owns an in-office infusion suite and manages a meaningful volume of biologic-treated patients can earn $200,000–$600,000 more per year than an employed counterpart performing identical clinical work. That income differential, driven by the buy-and-bill model for infliximab biosimilars, rituximab, sarilumab, and other Part B biologics, is the defining financial variable in rheumatology practice ownership — and the one most often misunderstood or ignored at career entry.

Training length is meaningful but not extreme: three years of internal medicine residency followed by two to three years of rheumatology fellowship puts most rheumatologists into practice between ages 31 and 34. Unlike surgical subspecialties requiring six or eight years of post-residency training, the rheumatology training timeline is not dramatically later than internal medicine attendings — but the initial attending income is substantially lower. This income gap, combined with six-figure loan balances arriving at attending, makes the early career financial decisions — PSLF vs. refinance, employed vs. private practice, infusion ownership vs. hospital infusion — disproportionately consequential.

The defining structural split: approximately 60–65% of practicing rheumatologists are employed by academic medical centers, nonprofit hospital systems, or group practices affiliated with nonprofit health systems — making rheumatology one of the more hospital-employed non-procedural specialties and one of the most reliably PSLF-eligible.¹ The remaining 35–40% in private practice or PE-backed platforms face a very different financial planning environment, where infusion ownership and practice structure become the dominant wealth-building levers.

Rheumatologist Income by Practice Setting

PSLF for Rheumatologists: When It Applies and When It Doesn't

Public Service Loan Forgiveness requires full-time employment at a qualifying 501(c)(3) nonprofit, federal government entity, or other qualifying public service organization. For rheumatologists, eligibility follows the same nonprofit/for-profit employment divide that governs all physician PSLF eligibility — but the high concentration of rheumatologists in academic and hospital settings makes PSLF a realistic path for a majority of the specialty.

PSLF-eligible rheumatology settings:

• Academic medical centers: University rheumatology faculty employed directly by a 501(c)(3) academic health system qualify. Verify the employer on your W-2 — some academic-affiliated practices are organized as separate professional corporations that may or may not be nonprofit entities. The university hospital name on your door is not sufficient; the legal employer on the W-2 is what matters to MOHELA.
• Nonprofit hospital systems: Rheumatologists employed by qualifying nonprofit health systems — those whose W-2 is issued by the 501(c)(3) entity — are PSLF-eligible. HCA, LifePoint, and other for-profit chains do not qualify; Mayo Clinic, Cleveland Clinic, mass-market nonprofit systems, and most regional nonprofit health systems do. Verify the employer's 501(c)(3) status on IRS Form 990 if uncertain.
• VA rheumatologists: Federal government employment qualifies for PSLF. VA rheumatology positions also qualify for the VA's Education Debt Reduction Program (EDRP), which provides up to $200,000 in loan repayment assistance over five years — and EDRP payments can stack with PSLF eligibility at the same VA position. VA employment provides the strongest loan forgiveness stacking in rheumatology.
• FQHCs and rural health clinics: A small number of federally qualified health centers and rural clinics employ rheumatologists for underserved populations. Physicians directly employed by a 501(c)(3) FQHC qualify for PSLF; some may also qualify for NHSC Loan Repayment Program (NHSC LRP) if they have a primary care designation — though rheumatology is generally not considered primary care by HRSA and most rheumatologists will not qualify for NHSC directly.

Not PSLF-eligible: Private practice groups, PE-backed platforms (all are organized as for-profit entities), and any rheumatologist whose W-2 is issued by a for-profit employer are ineligible for PSLF regardless of the clinical mission of the practice.

For rheumatologists entering private practice or PE-backed platforms, PSLF is not available and the loan strategy shifts to refinancing. With a 5–6 year training period, loan balances arrive at attending with accumulated interest capitalization. Refinancing at current attending rates (typically 4.5–6.5% for physicians with strong income and minimal default risk) and applying the first attending years' income premium to accelerated principal paydown is the standard approach. See the Physician Student Loan Refinancing Guide and the OBBBA Physician Student Loan Impact Guide for the July 2026 Grad PLUS elimination context.

In-Office Biologic Infusion: The Rheumatology Income Multiplier

Biologics — including infliximab biosimilars (Inflectra, Renflexis, Avsola, and others), rituximab biosimilars (Truxima, Ruxience, Riabni), sarilumab (Kevzara), abatacept (Orencia), tocilizumab (Actemra), and belimumab (Benlysta) — are administered by infusion or injection in the physician's office and covered under Medicare Part B (not Part D) when given in a physician office setting. This Part B coverage structure enables the buy-and-bill model: the physician's practice purchases the drug directly, administers it, bills Medicare for the drug (at ASP+6%) plus the infusion administration code, and retains the margin between acquisition cost and reimbursement.

How the Buy-and-Bill Model Works

Under Medicare's Part B drug reimbursement framework, physician-administered biologics are reimbursed at the drug's average sales price plus 6% — a margin designed to cover acquisition, storage, and handling costs. The physician practice buys the drug from a specialty pharmacy distributor at or near the ASP and bills Medicare (and applicable secondary payers) at ASP+6%.

The margin per infusion in a private rheumatology practice varies substantially by drug, biosimilar vs. reference product, payer mix, and volume-based purchasing agreements with distributors. Infliximab biosimilars — now the most commonly infused biologic in rheumatology — carry lower per-unit margins than the original Remicade due to biosimilar competition compressing ASP, but higher volume makes up for the compressed margin. Commercial insurance reimbursement for biologics is typically higher than Medicare, and many commercial payers negotiate separate contracted rates for physician-administered drugs that exceed the Medicare ASP+6% floor.

A rheumatology practice infusing 30–50 biologic doses per month across its patient panel — a moderate volume for a busy private practice — can generate $150,000–$400,000 in annual net revenue from infusion after drug acquisition costs, infusion nursing staff, chair and equipment costs, and billing overhead. A high-volume practice with 80–120 doses per month, strong commercial payer mix, and efficient operations can clear $400,000–$700,000+ in net infusion income annually. This income is in addition to the physician's professional fee for the office visit associated with each infusion encounter.

The 340B Competitive Dynamic

Hospital-based rheumatology infusion programs affiliated with qualifying covered entities — nonprofit hospitals, FQHCs, and certain other organizations — can access 340B drug pricing, which provides drug acquisition costs dramatically below the market price. Under 340B, a hospital outpatient department can acquire the same biologic at a fraction of the cost and bill Medicare at ASP+6%, generating a much higher margin per dose than a private practice paying full market price.

This 340B advantage creates a structural disadvantage for private practice rheumatologists in certain markets — hospital-employed rheumatology infusion programs can undercut on patient cost-sharing and still generate substantial institutional margin. However, 340B does not eliminate the private practice infusion opportunity: commercial insurance reimbursement does not follow the 340B framework in the same way, private payer contracting can offset the Medicare margin disadvantage, and volume-based distributor agreements narrow the gap. Private practice rheumatologists building infusion programs should model payer mix carefully before projecting infusion revenue, and should engage a healthcare attorney to structure the infusion program compliantly.

Infusion Center vs. Referring to Hospital Outpatient

Rheumatologists who refer patients to hospital outpatient infusion departments rather than building their own in-office infusion capacity give up the buy-and-bill margin entirely. The clinical rationale for hospital referral is sometimes legitimate — complex patients requiring ICU backup, certain high-risk first infusions — but for routine maintenance infusions in stable patients, hospital outpatient referral is primarily a financial decision that transfers substantial income from the physician to the hospital system. A rheumatologist in private practice who refers all infusions to the hospital over a 20-year career at $200,000/year in foregone infusion margin leaves $4,000,000 in unrealized income on the table (pre-tax). This is not a typical financial planning calculation, but it is the correct framing for a rheumatologist deciding between academic employment, hospital employment, and private practice.

Retirement Account Stacking for Rheumatology Practice Owners

For rheumatologists who own their practice — whether a traditional private group or an infusion-enabled solo or small-group practice — the 2026 retirement account stacking opportunity is substantial:

A rheumatologist practice owner in their mid-50s earning $600,000 combined from practice fees and infusion operations can realistically shelter $170,000–$260,000 per year through the full account stack. At a 37% marginal federal rate, that represents $63,000–$96,000 in annual federal tax reduction on the deferred amounts. Over a 10-year peak-earning window, the cumulative tax deferral from full stacking substantially exceeds any reasonable investment alpha from active management. No financial planning move for high-income practice-owning rheumatologists has a higher expected return per dollar than executing this stack correctly.

The December 31 adoption deadline is non-negotiable: both the solo 401(k) and the cash balance plan must be formally adopted before December 31 of the year in which contributions are claimed. A record infusion revenue year discovered in January is too late for the solo 401(k) adoption for that year. Review plan adoption timing every October. See the Solo 401(k) for Physicians Guide and Cash Balance Plan for Physicians Guide.

Retirement Planning for Hospital-Employed Rheumatologists

Rheumatologists employed by nonprofit health systems access a different but still meaningful set of vehicles. The 2026 combined 403(b) + governmental 457(b) employee deferral for physicians at nonprofit hospitals offering both plans is $49,000 ($24,500 + $24,500), more with age catch-ups. This is lower than the practice-owner stack, but it meaningfully reduces AGI — which directly lowers IBR payments for PSLF-track rheumatologists. The interaction between 403(b)/457(b) contributions and PSLF forgiveness is often worth more than the tax deferral alone: every dollar of 403(b) deferral that reduces AGI produces a proportional reduction in IBR payments for the life of the PSLF window, increasing the forgiven balance at month 120. See the PSLF Payment Tracker Calculator to model your specific scenario.

S-Corp Election for Rheumatology Practice Owners

A rheumatologist operating as a sole proprietor or single-member LLC pays self-employment tax (15.3% up to the $184,500 Social Security wage base in 2026, then 2.9% Medicare on all earned income above) on all net practice income including infusion profits. An S-corp election allows splitting practice and infusion income between a W-2 salary — subject to FICA — and K-1 distributions from the S-corp, which are not subject to FICA or self-employment tax.

For a rheumatologist earning $550,000 net from practice fees plus infusion margin: electing S-corp status, setting a reasonable W-2 of $275,000, and taking the remaining $275,000 as K-1 distributions eliminates FICA on the distribution. The savings on the Medicare portion alone (2.9% × $275,000 = $7,975) plus any Social Security FICA above the wage base is meaningful — but the larger benefit is that the employer profit-sharing 401(k) contribution (25% of W-2 under S-corp) is $68,750, maximizing the §415 annual additions limit and the cash balance plan foundation. The S-corp structure must be properly maintained: payroll, quarterly estimated taxes, reasonable compensation documentation, and state filing requirements. A CPA specializing in physician practice owners is essential. Use the S-Corp Tax Savings Calculator for a preliminary estimate.

Private Equity Consolidation in Rheumatology

Private equity consolidation in rheumatology is earlier-stage than in gastroenterology, orthopedics, or dermatology — but it is accelerating. The infusion revenue component of rheumatology practices is the primary PE value driver: a practice with a profitable infusion program represents a more attractive acquisition than a purely cognitive rheumatology office, because the infusion revenue is scalable, recurring, and technology-independent. PE buyers are specifically targeting infusion-enabled rheumatology practices.

US Rheumatology is among the most active PE-backed rheumatology consolidation platforms in the United States, with a growing footprint across multiple states. Other regional platforms and independent practice management companies are acquiring rheumatology groups in markets with fragmented physician ownership. The acquisition pace has increased materially in 2024–2026 as PE sponsors recognize the infusion revenue model as a durable cash-flow asset.²

The typical rheumatology PE transaction follows the MSO model: the management services organization acquires the non-clinical assets and management function, while you retain the professional entity. You receive cash at close and roll a minority equity stake into the platform entity.

Personal Goodwill in Rheumatology Practice Sales

In a rheumatology practice sale, the patient relationships, clinical reputation, infusion program referral base, and physician continuity represent personal goodwill — value that belongs to the individual physician, not the practice entity. Personal goodwill sold directly by the physician is taxed at long-term capital gains rates (23.8% including NIIT), rather than at ordinary income rates (up to 37%). For a rheumatology practice sale in the $1.5M–$4M range, proper personal goodwill allocation before the letter of intent can reduce federal taxes by $200,000–$500,000 depending on the goodwill proportion and total transaction size. This allocation must be structured and documented before the LOI is executed — retroactive restructuring is extremely difficult. See the Physician Private Equity Buyout Guide for transaction mechanics.

Valuing Infusion Revenue in a PE Transaction

The infusion program is the highest-multiple component of a rheumatology practice valuation in the current PE environment. Buyers typically apply a higher EBITDA multiple to recurring infusion revenue than to professional fee revenue, because infusion revenue is more predictable (stable chronic patients, recurring biologic maintenance dosing) and less physician-dependent than new patient volumes. However, infusion revenue carries two meaningful valuation risks: biosimilar pricing pressure (as more infliximab and rituximab biosimilars enter the market, ASP falls and buy-and-bill margins compress) and payer mix sensitivity (commercial infusion reimbursement is significantly higher than Medicare, and commercial payer contract changes can move practice economics materially).

In a PE negotiation, understand how the buyer is projecting infusion revenue trends and what sensitivity assumptions are built into their valuation model. If the buyer is applying a high multiple to infusion revenue using a static reimbursement assumption, and you believe biosimilar pricing will continue to compress that margin, the valuation may be generous today and will not repeat at the next liquidity event. Independent financial modeling of your infusion revenue trajectory — separate from the PE buyer's model — is necessary for evaluating deal terms. Engage a healthcare M&A financial advisor alongside your transaction attorney.

QSBS on Rollover Equity

Rollover equity into a PE-backed rheumatology platform may qualify for Qualified Small Business Stock treatment under IRC §1202. After OBBBA (effective July 2025), the QSBS exclusion is permanently $15 million per taxpayer, with a tiered structure: 50% exclusion at three years, 75% at four years, 100% at five years. If the platform entity is a qualified C-corp and rollover equity is properly structured at close, appreciation on that rollover equity at the next liquidity event may be partially or entirely tax-free. QSBS eligibility is determined at issuance — it cannot be retroactively structured. Verify eligibility and structure with a tax attorney before signing any purchase agreement. See the Physician PE Buyout Guide.

Non-Governmental 457(b) Risk at PE Platforms

Some PE-backed rheumatology platforms offer non-governmental deferred compensation arrangements to physician employees. Non-governmental 457(b) balances are general assets of the employer corporation — if the platform enters financial distress, deferred compensation participants become unsecured creditors. Leveraged PE buyouts, particularly those transacted at high EBITDA multiples in a rising-rate environment, carry real financial risk. Do not accumulate large non-governmental 457(b) balances at a PE platform without evaluating the platform's capital structure, debt coverage, and financial stability. See the Physician 457(b) Deferred Compensation Guide.

Disability Insurance for Rheumatologists

Rheumatology is primarily a cognitive and office-procedural specialty. Unlike surgical specialties where manual dexterity is existential to practice, rheumatology involves joint examination, ultrasound-guided injections, patient counseling, and interpretation of labs and imaging — activities that require hand function and mobility but are less technically demanding than endoscopy or surgery. The own-occupation definition still matters significantly, but the total disability risk profile is lower than for procedural surgery subspecialties.

Own-Occupation Definition for Rheumatologists

A true own-occupation policy pays benefits if you cannot perform the material and substantial duties of your specific occupation as a rheumatologist — even if you can work in another medical capacity. For rheumatologists who perform significant volumes of ultrasound-guided joint injections, aspirations, and small joint procedures, a hand or wrist injury that prevents fine-motor procedural work could constitute partial disability under an own-occupation policy even if clinical consultation and biologic management work continues. The income associated with the procedural component of rheumatology — and especially the infusion program — is worth protecting separately through a true own-occupation policy with a residual/partial disability rider.

Key riders for rheumatologists:

• Future Increase Option (FIO): Purchase during fellowship or early attending years when income is lowest and insurability is easiest. Locks in the right to increase coverage as income grows without new medical underwriting. The FIO window closes; do not let it lapse through the first attending year without acting.
• Residual/Partial Disability: Particularly relevant for rheumatologists with infusion income. A partial disability that affects your ability to manage a full infusion schedule or perform joint injection procedures could reduce total income by 30–50% without fully disabling you. Residual benefits cover the proportional income reduction.
• COLA Rider: Indexes the benefit amount to inflation during a claim. Rheumatology careers span 25–35 years; inflation protection matters for any long-term disability scenario starting in early career.

Malpractice Insurance for Rheumatologists

Rheumatology carries relatively low malpractice risk compared to procedural and surgical specialties. Office-based rheumatology without significant procedural volume typically generates annual premiums of $5,000–$12,000 depending on state, coverage limits, and procedure mix. Rheumatologists who perform frequent joint injections and aspirations, or who manage high-risk biologic therapies (TNF inhibitors in immunocompromised patients), may carry somewhat higher premiums reflecting infection and adverse event risk associated with these interventions.³

If you are leaving an employer — to enter private practice, join a PE platform, or retire — and you carry a claims-made policy, tail coverage is required to protect against future claims from prior work. Tail coverage typically costs 150–250% of the final-year claims-made premium as a lump sum. In a PE acquisition, the responsibility for tail coverage on prior claims-made policies should be explicitly negotiated in the purchase agreement. See the Physician Malpractice Insurance Guide for structural details.

7 Financial Mistakes Rheumatologists Make

1. Failing to build an in-office infusion program in private practice — or not understanding its economics before choosing an employment model. The most consequential career-stage decision for many rheumatologists is made at fellowship graduation, often without quantifying the infusion income differential. A rheumatologist who joins a hospital system for the stability and never builds an infusion-enabled private practice may be accepting $150,000–$400,000/year in foregone income relative to a private practice peer. This is not the right choice for every rheumatologist — PSLF, academic mission, lifestyle, and geography all matter — but it should be an explicit financial decision, not a default.
2. Not certifying PSLF from the first year of training at a qualifying nonprofit program. The five to six years of internal medicine residency plus rheumatology fellowship at nonprofit academic medical centers are among the most valuable PSLF years of any physician career — training income is low, IBR payments are minimal, and the qualifying-payment clock runs continuously. A rheumatologist with $230,000 in loans who spends five years in fellowship at a nonprofit and then joins a qualifying employer as an attending can have 60 of 120 payments completed before day one as an attending — with $75,000 or less paid on a balance that would require $350,000+ standard repayment. Failing to certify PSLF employer status from year one forfeits the compounding value of those training years permanently.
3. Operating as a sole proprietor without S-corp election after reaching substantial infusion income. Rheumatologists with meaningful infusion revenue flowing through a sole proprietorship pay self-employment tax on every dollar of net infusion income. An S-corp election — with a reasonable W-2 salary and K-1 distributions on infusion profits — eliminates FICA on the distribution component and unlocks a larger 401(k) employer profit-sharing contribution. At $500,000+ in combined practice and infusion income, the annual tax cost of not electing S-corp is typically $8,000–$15,000 in avoidable FICA. Generalist accountants frequently miss this in the first years of private practice.
4. Not establishing a cash balance plan at peak infusion-revenue years. Rheumatologists with infusion programs at ages 45–55 often have both the income and the time horizon to shelter $150,000–$250,000/year above the solo 401(k) limit in a well-designed cash balance plan. Many never learn this vehicle exists because their general financial advisor or CPA doesn't work with physician practice owners. Over a 10-year window before a PE transaction or planned practice exit, the missed deduction is $1.5M–$2.5M in forgone tax deferral — equivalent to $555,000–$925,000 in federal taxes paid unnecessarily at the 37% marginal rate.
5. Entering a PE letter of intent without separating personal goodwill first. Personal goodwill in a rheumatology practice — patient relationships, clinical reputation, infusion program continuity — typically constitutes a substantial proportion of total practice value. Once the LOI is executed at a combined practice-and-goodwill valuation, reallocating between enterprise and personal goodwill becomes extremely difficult without renegotiating the total price. The difference between allocating $800,000 to personal goodwill (taxed at 23.8%) vs. ordinary income (37%) is $105,000 in federal taxes on that component alone. In a $2.5M–$5M rheumatology practice transaction, proper goodwill allocation is often the single highest-value financial decision in the transaction.
6. Accumulating large non-governmental 457(b) balances at a PE-backed platform without assessing financial stability. PE-backed rheumatology platforms often carry significant acquisition debt from the LBO transaction. Non-governmental deferred compensation is an unsecured liability of the employer. If the platform encounters financial stress from rising interest rates, biosimilar pricing pressure, or payer contract deterioration, 457(b) participants have no priority claim on deferred assets. Spreading deferred compensation across multiple vehicles — qualified plan, taxable account, Roth — is meaningfully safer than concentrating retirement assets in a leveraged employer's non-governmental plan.
7. Underestimating biologic-related liability exposure when building an infusion program. In-office biologic infusion creates specific liability exposure that differs from typical office-based rheumatology: infusion reactions, infection risk in immunocompromised patients receiving TNF inhibitors, adverse events from high-risk biologics in patients with complex comorbidities, and the regulatory requirements associated with maintaining an infusion suite. Malpractice coverage should be reviewed with an insurer who understands infusion-enabled rheumatology practice — a generic rheumatology policy written without infusion-volume consideration may have coverage gaps. Incident reporting and adverse-event documentation protocols appropriate for an infusion program should be in place before the first commercial biologic is administered.

Action Plan by Career Stage

Internal Medicine Residents and Rheumatology Fellows

• Certify PSLF employer status from your first year of training if your program is at a qualifying 501(c)(3) academic medical center or nonprofit hospital. Even if you are uncertain about long-term employment setting, the cost of certification is zero and the downside of forfeiting qualifying training payments is large. Submit your Employment Certification Form to MOHELA before your first IBR payment.
• Open a Roth IRA every year of training while income stays below the direct contribution phase-out ($153,000–$168,000 for single filers in 2026). Resident and fellow income is reliably below this threshold. Roth contributions during training become the only decade-plus of tax-free compounding you will accumulate before the backdoor strategy is required — the value compounds for decades.
• Buy individual own-occupation disability insurance with the FIO rider before fellowship ends. Locking in insurability and specialty classification while you are young and healthy matters. The FIO right to increase coverage as attending income grows is lost once you pass the window or experience a qualifying health event. Do not defer this past the first attending year.
• Research infusion center economics before choosing your first practice. Talk to practicing rheumatologists who own infusion programs about their buy-and-bill setup, payer contract experience, and net income from infusion. This is the single most underdiscussed financial topic in rheumatology fellowship, and the most consequential career-stage decision for long-term wealth.

Early-Career Attending Rheumatologist (Years 1–5)

• If hospital or academic-employed with PSLF eligibility: certify employment with MOHELA immediately. Max both the 403(b) and governmental 457(b) — the combined $49,000 pre-tax deferral reduces AGI and lowers IBR payments simultaneously, compounding the PSLF benefit.
• If entering private practice: elect S-corp status and open a solo 401(k) in year one before December 31. The plan must be adopted before December 31 of the contribution year. Designate a CPA familiar with physician practice owners before practice formation.
• If building an infusion program: engage a healthcare attorney to structure the program compliantly, review your malpractice policy with an infusion-aware carrier, and model payer mix before projecting income. The first one to two years of an infusion program involve setup costs and ramp time; plan for 12–18 months before the program reaches steady-state economics.
• Read the New Attending Physician Financial Checklist at least six months before your first contract is signed.

Mid-Career Rheumatologist (Years 5–15)

• If you have not established a cash balance plan alongside the solo 401(k), evaluate it now. The contribution capacity at ages 45–55 is highest relative to remaining runway. A practice-owning rheumatologist at 52 earning $650,000 combined can shelter $175,000–$230,000/year in a well-designed cash balance plan on top of the solo 401(k). Model this with a CPA and enrolled actuary who specialize in physician-owned practices.
• If PE acquisition discussions are beginning: engage independent legal and financial counsel before any LOI. Personal goodwill separation, infusion program valuation, QSBS eligibility for rollover equity, and pre-close retirement stacking all require months of preparation that cannot be compressed after terms are exchanged. See the Physician Practice Exit Planning Guide.
• Model IRMAA exposure on a contemplated practice sale. A large transaction pushing Modified AGI above IRMAA thresholds in the sale year triggers Medicare surcharges two years later. Installment sale structures, charitable vehicles, or transaction-year income spreading can moderate this. See Physician IRMAA Medicare Planning.

Late-Career Rheumatologist (Years 15+)

• Cash balance plan contributions peak in your late 50s and early 60s. A 62-year-old rheumatologist with an infusion program can contribute $200,000–$280,000/year to a cash balance plan — accumulating $1M+ in pre-tax assets in five years before a planned practice sale. Pre-close stacking is most effective when the plan has been in place for several years before the sale year; don't start the plan the year you plan to sell.
• Update estate planning. The current $15 million estate exemption (OBBBA, permanently effective) means federal estate tax is not a concern for most rheumatologists, but practice buy-sell agreements, qualified plan beneficiary designations, and any trust structures established under prior law need current review. See Physician Estate Planning Guide.
• Model Social Security claiming timing relative to the practice exit year. Retiring or selling at 62–65 creates a 5–8 year Roth conversion window before RMDs begin — ideal for filling low tax brackets while delaying Social Security to 70 to maximize the monthly benefit ($5,181/month at 2026 benefit levels for high-40-year earners). See Physician Social Security Optimization Guide.